| abstract |
The present invention provides isolated anti-human NKG2D monoclonal antibodies useful as therapeutics in humans. Typically, the antibody is a fully human or humanized antibody to minimize the risk of an immune response to the antibody when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules may be designed or derived from such antibodies. |